Ovarian Preservation Doesn't Impact Prognosis in Cervical CA

Share this content:
Ovarian Preservation Doesn't Impact Prognosis in Cervical CA
Ovarian Preservation Doesn't Impact Prognosis in Cervical CA

THURSDAY, Oct. 13, 2016 (HealthDay News) -- For women with early-stage cervical adenocarcinoma, ovarian preservation does not impact survival, according to a study published in the October issue of the American Journal of Obstetrics & Gynecology.

Jing Chen, M.D., from Huazhong University of Science and Technology in Wuhan, China, and colleagues examined the impact of ovarian preservation on prognosis in a retrospective study involving 194 women with cervical adenocarcinoma. Follow-up was completed for 159 women. The authors compared the impact of ovarian preservation on prognosis for 33 women with ovarian preservation and 126 who underwent bilateral salpingo-oophorectomy.

The researchers found that survival did not differ significantly for women with bilateral salpingo-oophorectomy and ovarian preservation (P = 0.423 for disease-free survival and P = 0.330 for overall survival). Significant independent prognostic factors related to poor disease-free survival included tumor size (>4 cm), deep cervical stromal invasion, and lymph node metastasis; lymph node metastasis correlated with overall survival. There was a significant difference in the relationship between ovarian metastasis and deep cervical stromal invasion, lymph node metastasis, and parametrial invasion among the 153 women with cervical adenocarcinoma who underwent bilateral salpingo-oophorectomy. In meta-analysis of the literature, clinical stage IIB versus I to IIA, deep stromal invasion, lymph node metastasis, corpus uteri invasion, and parametrial invasion correlated with ovarian metastasis.

"Ovarian preservation has no effect on prognosis in women with early-stage cervical adenocarcinoma," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Actemra to Treat Giant Cell Arteritis

FDA Approves Actemra to Treat Giant Cell Arteritis

New indication provides the first FDA-approved therapy specific to this type of vasculitis

Trends in Teen Binge Drinking Still Raise Concerns

Trends in Teen Binge Drinking Still Raise Concerns

Even though frequent binge drinking among adolescents has dropped in past 25 years

ATS: First Abx Rx Doesn't Work for 25 of Pneumonia Cases

ATS: First Abx Rx Doesn't Work for ~25% ...

One in four adult patients do not respond to initial prescription of antibiotic treatment

is free, fast, and customized just for you!

Already a member?

Sign In Now »